TGA approves Australia's first oral GLP-1 weight-loss tablet

The TGA approved the first oral GLP-1 weight-loss tablet for Australia on Tuesday 3 November 2026 — a once-daily oral form of semaglutide under the brand name Wegovy. Until this week, Australians with a prescription for a GLP-1 weight-loss drug had one delivery route: a weekly subcutaneous injection. That changes with this approval, though not immediately, and not cheaply.

If you have been managing your weight with your GP and either started or considered a GLP-1 drug, this is worth knowing about — not as a prompt to act right now, but as a marker that the landscape is shifting.

What was approved, and what it means

The TGA approved four oral strengths of Wegovy: 1.5 mg, 4 mg, 9 mg and 25 mg. The 25 mg tablet delivers a broadly equivalent effect to the 2.4 mg injection, because the gut absorbs semaglutide far less efficiently when swallowed than when injected under the skin. The approved indications cover people with obesity and people seeking cardiovascular risk reduction.

A prescription is required. The product is not yet on pharmacy shelves — the TGA still needs to clear the packaging and production processes before Novo Nordisk can begin supply. The company has stated that Australia is a priority market, so availability is expected within months rather than years.

The approval follows earlier clearances in the United States and Europe. In those markets, the oral form launched to strong demand. It competes with Eli Lilly’s oral GLP-1, orforglipron, which is awaiting its own TGA decision — meaning Australia may have two oral options in this category before long.

Both-and: what this opens and what it doesn’t

The case for the oral form is real. For anyone who has hesitated to start an injectable GLP-1 because of needle aversion, the daily tablet is a meaningful alternative. It may also be easier to manage for people who travel, who find weekly injection timing difficult, or who experience injection-site reactions. Those are not trivial factors.

The complication — and it is a significant one — is PBS access. Semaglutide as an injectable is listed on the Pharmaceutical Benefits Scheme for people with type 2 diabetes, under criteria tied to HbA1c thresholds and prior use of other agents. It is not subsidised for obesity in people who do not have type 2 diabetes. The oral form enters with the same gap: approved by the regulator, not yet covered for weight management. No Australian price has been announced, but in the US the tablet has generally been less expensive than the injection — which suggests a lower private cost, not a subsidised one.

Australian prescribing guidance for GLP-1 agents in obesity management is being actively developed, and the evidence base is strong. The SELECT trial, which studied semaglutide in people with obesity and cardiovascular disease but without type 2 diabetes, showed significant reductions in major cardiovascular events. That evidence supported the cardiovascular indication in the TGA approval. It has not yet moved PBS criteria.

This matters for the 45-year-old woman in a GP consult who is managing her weight, perhaps alongside elevated cholesterol, blood pressure, or early metabolic changes at perimenopause. The clinical evidence supports using a GLP-1 in that context. The access route — private prescription, out-of-pocket cost — may make it inaccessible. The system has approved the drug without yet building the subsidy pathway.

The GLP-1 conversation is broader than this

Separately, a newsGP survey published today found that 52% of GPs report a patient has previously failed to disclose their GLP-1 use to them. That figure matters alongside this approval. If more people gain access to oral GLP-1 agents through private prescriptions from telehealth providers — a trend that has accelerated alongside the injectable shortage and cost concerns — undisclosed use will continue to create safety risks, particularly around surgery preparation and drug interactions.

There is a clinical duty to screen before prescribing these agents, and that includes screening for eating disorder risk. GLP-1 receptor agonists can be misused by people with restrictive eating disorders who are seeking appetite suppression as a tool for further restriction. Atypical anorexia nervosa — which occurs in people in larger bodies — is frequently missed, and GPs are the most likely point of detection.

The oral form does not change these clinical obligations. It changes the barrier to access.

2 cents

The oral Wegovy approval is genuine progress for people who want an effective weight management tool and prefer not to inject. It is also a gap in the same system: approved, not subsidised, not yet available.

The practical near-term question for anyone considering a GLP-1 is not whether a tablet beats an injection — for most people, either form is acceptable if they can access and tolerate it. The question is what your GP can prescribe under PBS, what it will cost privately if PBS criteria are not met, and whether the clinical rationale in your case is documented clearly enough to support a streamlined authority application when that pathway exists.

If this is a conversation you have been putting off because of the injection component, the oral form makes it worth revisiting with your GP once availability is confirmed.

Verdict: yes — a meaningful regulatory milestone that changes the conversation, not yet the access.

---

Sources cited

1. Daily weight loss tablet Wegovy cleared by TGA for use in Australia — ABC News, 3 November 2026
2. NPS MedicineWise — GLP-1 receptor agonists
3. Australian Prescriber — semaglutide